Financial Performance - The company's operating revenue for 2022 was CNY 4,041,818,347.54, representing a 5.01% increase from CNY 3,848,985,686.56 in 2021[12]. - The net profit attributable to shareholders for 2022 was CNY 779,998,116.10, a significant increase of 77.10% compared to CNY 440,439,963.60 in 2021[12]. - The basic earnings per share for 2022 was CNY 1.21, up 77.94% from CNY 0.68 in 2021[12]. - The total assets at the end of 2022 amounted to CNY 12,631,382,359.34, an increase of 8.63% from CNY 11,628,031,898.88 at the end of 2021[12]. - The net profit after deducting non-recurring gains and losses for 2022 was CNY 699,829,938.05, an increase of 98.60% from CNY 352,383,752.92 in 2021[12]. - The company reported a net profit of CNY 267,099,762.61 in Q4 2022, with a net cash flow from operating activities of CNY 856,590,701.17[15]. - The company achieved a weighted average return on equity of 7.68% in 2022, up from 4.46% in 2021[12]. - The company reported a total of ¥4,640,000,000.00 in new purchases of trading financial assets during the reporting period, with a total of ¥5,240,000,000.00 sold[46]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2022, representing a year-over-year increase of 15%[124]. Cash Flow and Investments - The net cash flow from operating activities for 2022 was CNY 2,144,878,185.39, a decrease of 23.42% from CNY 2,800,902,528.25 in 2021[12]. - Cash and cash equivalents increased by 42.48% to ¥2,296,636,668.76[42]. - Investment activities generated a net cash flow of ¥589,507,998.15, a significant increase of 161.24% compared to the previous year[42]. - The company has a total of 30,000,000 CNY in principal guaranteed floating income products with an actual profit of 561.38 CNY[121]. - The company has entrusted 464,000 million RMB in bank wealth management products, with an unexpired balance of 185,000 million RMB[120]. Product Development and Market Strategy - The company has launched new products such as "Peach Blossom Princess" Ejiao cake and "Dong'e Ejiao" powder, targeting high-end female consumers and younger demographics[19][20]. - The company is focusing on expanding its market presence and product offerings in response to the growing demand for traditional Chinese medicine[18]. - The company is actively pursuing new product development and technological advancements to enhance its product offerings and market competitiveness[68]. - The company plans to enhance product differentiation and quality research, aiming to build competitive barriers and expand into multiple product categories[52]. - The company is considering strategic acquisitions to enhance its market position, with a budget of 500 million RMB allocated for potential deals[124]. Research and Development - The company is actively involved in research projects, including the clinical value assessment of Ejiao in treating cancer-related fatigue, which has shown significant improvement in patients' quality of life[21]. - The company has ongoing R&D projects aimed at developing traditional Chinese medicine products and health products, with significant clinical research backing[38]. - The company invested 200 million RMB in R&D for new technologies aimed at enhancing product efficacy and user experience[125]. - Research and development expenses decreased to ¥137,705,813.17 in 2022 from ¥147,749,402.42 in 2021, a decline of 6.9%[165]. Governance and Management - The company adheres to strict governance practices, ensuring compliance with relevant laws and regulations, and maintaining independence from its controlling shareholder[56][59]. - The company has established a reasonable mechanism for selecting its management team, ensuring clear responsibilities and accountability[58]. - The company has maintained a stable board of directors, with all current members serving until June 28, 2024[61]. - The company has conducted multiple investor communications, discussing overall business conditions, product positioning, and marketing strategies[55]. - The company reported a significant leadership change with the resignation of former Chairman and CEO Gao Dengfeng on February 20, 2023, due to work-related reasons[62]. Environmental and Social Responsibility - The company invested 5.26 million yuan in environmental governance and protection in 2022, with water resource tax expenditures amounting to 2.1529 million yuan[105]. - The company generated 3.731 million kWh of solar power in 2022, accounting for 16.07% of the total electricity consumption in the industrial park, resulting in a reduction of 3,720 tons of CO2 emissions[105]. - The company has a 100% monitoring rate, compliance rate, and disclosure rate for wastewater, waste gas, and noise monitoring[105]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[107]. Shareholder Information - The total number of shares held by Liu Guangli, a supervisor, increased by 900 shares during the reporting period[62]. - The total number of shares outstanding remained at 654,021,537, with no changes in shareholder structure[133]. - The largest shareholder, China Resources Dong'e Ejiao Co., Ltd., holds 151,351,731 shares, accounting for 23.14% of the total share capital[137]. - The company distributed dividends totaling ¥196,206,407.94 to shareholders during the year[175]. Financial Reporting and Compliance - The audit opinion issued by Ernst & Young was a standard unqualified opinion, confirming that the financial statements fairly reflect the company's financial position[146]. - The financial statements were approved by the board of directors on March 23, 2023, ensuring compliance with accounting standards[178]. - The company has maintained effective internal controls over revenue recognition and accounts receivable management[150]. - The company has not reported any penalties from regulatory authorities for its directors and supervisors in the last three years[73].

证券代码：000423 证券简称：东阿阿胶 公告编号：2023-17 东阿阿胶股份有限公司 关于召开 2022 年年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1．会议时间：2023 年 03 月 27 日（星期一）16:00-17:30 4．问题征集：投资者可于 2023 年 3 月 26 日（星期日）12:00 前访问网址 https://eseb.cn/13hoe1OKPO8 或使用微信扫描下方程序码，办理预约报名等手 续。在预约报名时可进行会前提问，公司将通过本次业绩说明会，在信息披露允 许范围内就投资者普遍关注的问题进行回答。 东阿阿胶股份有限公司（以下简称"公司"）已于 2023 年 3 月 25 日披露了 《2022 年年度报告》。为便于广大投资者更加全面深入地了解公司经营业绩、发 展战略等情况，拟定于 2023 年 3 月 27 日举办 2022 年年度业绩说明会。具体内 容如下： 一、召开时间、地点和方式 3．召开方式：现场互动 二、出席人员 董事、总裁 程杰先生，董事、董事会秘书、副总裁、财务总监 邓 ...

Group 1: Product Development and Market Strategy - The company has launched a new category of oral beauty products with a price of 1,099 RMB per 30 grams, targeting the high-end market through premium retail channels [2] - The company is conducting pilot tests in Guangzhou and Shanghai to assess consumer acceptance and product stability in high-temperature and high-humidity environments [2] - The company is building two networks: a downstream marketing network and an upstream raw material network, with the latter being a long-term project due to the current shortage of donkey hide resources [3] Group 2: Pricing Strategy and Market Position - The retail price of donkey-hide gelatin has increased from 400 RMB to around 800 RMB per pound, indicating a shift towards a higher-end consumer demographic with greater brand loyalty [3] - The company has been conducting detailed planning and measurement for price adjustments over the past eight years, considering factors such as raw materials, industry trends, and consumer acceptance [3] - The company is confident in its market expectations, product strength, brand power, and service quality [3] Group 3: Regulatory Environment and Quality Standards - The company anticipates that the future modification of national quality standards will favor high-quality enterprises, enhancing their competitive edge [4] - The trend towards stricter standards in advanced economies, as seen in the U.S. during the 60s and 70s, is expected to influence China's regulatory environment positively [4] - Improvements in production processes and product quality standards will increase consumer trust in the company's products [4]

Group 1: Raw Material Challenges - The traditional Chinese medicine industry faces a bottleneck in raw materials, particularly in donkey farming, which is declining due to mechanization [2] - The company aims to establish a comprehensive raw material base as part of its 12th Five-Year Plan, focusing on improving efficiency in donkey farming [2] Group 2: Marketing Strategies - The company is enhancing cultural marketing and value return for its products, with a 53% price increase for the compound donkey-hide gelatin (Ejiao) approved by the pricing bureau [2] - The new packaging of Ejiao, offering 48 pieces per box, aims to demonstrate significant effects and is a breakthrough innovation [2] - Research investment in Ejiao has reached millions, focusing on clinical studies for various health benefits [2] Group 3: Product Development - The company is developing new products like "Peach Blossom Princess" and small molecule Ejiao, with plans for market testing in Guangzhou [3] - The company is collaborating with universities for research on the safety and efficacy of its products, including evaluations of Ejiao's effects on various health conditions [5] Group 4: Competitive Landscape - The company acknowledges increasing competition in the Ejiao market and plans to focus on leading the industry by expanding its product range [5] - The company is committed to maintaining its market position by supporting upstream suppliers and ensuring profitability for donkey farmers [5] Group 5: Government Support and Market Trends - The total number of donkeys has been declining at a rate of 3% annually, but local areas are seeing some recovery [6] - Government subsidies for donkey farming vary by region, with specific financial support for breeding programs [6] Group 6: Product Classification and Efficacy - Ejiao is classified as a medicine with proven pharmacological effects, primarily promoting hematopoietic stem cell activity [7] - The company is actively researching and validating the health benefits of Ejiao through collaborations with various institutions [7]

Group 1: Direct Sales Business Progress - The company is preparing a team and designing a direct sales plan for its direct sales business [1] - The development of direct sales will positively impact the expansion of product sales channels and scope [3] Group 2: Raw Material Resources - The overall trend of donkey resources is declining due to agricultural mechanization and urbanization [3] - Local government has introduced supportive policies to promote the donkey industry [3] - The company has innovated a new model for the circular development and utilization of live donkeys to enhance their economic value [3] - The company is increasing efforts to develop foreign raw material resources while leveraging existing import countries [3] Group 3: Product Sales Situation - **Ejiao**: Limited overall production due to raw material constraints; revenue is steadily increasing as the consumer base expands to new and high-end groups [3] - **Compound Ejiao Syrup**: Comprehensive analysis and evaluation were conducted in 2014, leading to repositioning in price, specifications, and channels to enhance market competitiveness [4] - **Peach Blossom Ejiao Cake**: Adjustments in price and specifications were made in response to rising raw material costs; marketing will focus on key markets in Shandong and Beijing, with plans for national expansion [4]

Group 1: Company Development and Product Strategy - The company has a dual focus on domestic and international raw material sourcing, enhancing the value of donkey hides through live-cycle development [2] - Small molecule Ejiao has shown good market potential through trial sales in direct stores and e-commerce [2] - The company has become the top health supplement brand on Taobao and plans to expand its e-commerce business further [2] Group 2: Research and Development - Collaborations with Japan's pharmaceutical university and Chinese Academy of Sciences are underway to validate Ejiao's efficacy in skin hydration and anti-smog effects [3] - Research on Ejiao's benefits for pregnant women and fertility has been initiated with international research centers [3] - Over 3,000 cancer anemia samples have been studied, showing that Ejiao can help prevent neutropenia during chemotherapy [3] Group 3: Internet Strategy and Marketing - The company ranks highly in online sales of mid-to-high-end health products and has established a dedicated e-commerce division [4] - Targeted marketing strategies focus on high-end consumers, utilizing traditional cultural values to engage younger demographics [4] - Small molecule Ejiao will undergo testing in Guangzhou, targeting young professional women in major cities [4] Group 4: Quality Control and Supply Chain Management - The company has established 20 demonstration bases for donkey breeding to ensure raw material quality and traceability [5] - Strict internal quality control standards exceed national requirements, and the company participates in drafting national quality standards for Ejiao [5] - The company is transitioning from a health product provider to a health service provider, enhancing consumer access to product quality information [5] Group 5: Cultural Value and Consumer Engagement - The company aims to create a health management chain that educates consumers about Ejiao's cultural significance and benefits [6]

Group 1: Company Overview - Dong-E E-Jiao Co., Ltd. held an investor relations activity on August 16, 2016, to discuss the company's operational status and financial indicators for the first half of 2016 [2][4]. - The meeting was attended by various institutional investors, including Huabao Investment Co., Ltd. and Goldman Sachs (Asia) LLC [2][4]. Group 2: Product Sales Performance - The sales of E-Jiao blocks remained stable during the adjustment period, focusing on cultural marketing and expanding consumer demographics [4][5]. - The Compound E-Jiao Syrup, as the longest-standing oral liquid product in China, has a solid market foundation and is being repositioned to enhance its competitiveness through marketing strategies [5][6]. - The Peach Blossom Princess E-Jiao Cake is targeting key markets in Shandong and Beijing, with innovations like the Peach Blossom Princess Year Card to boost sales [5][6]. Group 3: Raw Material Supply Chain - The domestic donkey resource is declining due to urbanization and agricultural mechanization, prompting the company to implement a full industry chain development strategy [5][6]. - The company is actively seeking government support to address funding, breeding, and sales issues for donkey farming, aiming to enhance the profitability of farmers [6]. Group 4: Financial Performance Insights - The decrease in operating cash flow is attributed to an increase in bank acceptance bills for sales collections, while cash outflows rose due to higher raw material reserve payments [6]. - The increase in inventory is mainly due to strategic reserves of raw materials [6]. - Accounts receivable and notes receivable grew due to annual credit assessments for sales customers, with a unified recovery at year-end [6].

Group 1: Marketing and Product Development - The company is focusing on modernizing its marketing strategies to adapt to changes in consumer purchasing channels, emphasizing the importance of innovation and new product development centered around traditional Chinese medicine [2][3] - The company aims to develop "Ajiao+" products to better serve consumers and expand its market reach [3] - The company is committed to enhancing research and development, including clinical studies to validate product efficacy, with projects like the integration of one million cases of compound Ajiao syrup [4] Group 2: Pricing and Market Strategy - The pricing of Ajiao products is expected to remain stable this year, but adjustments will depend on market conditions and external factors [3] - The company recognizes that Ajiao's daily consumption price is lower than other health products like cordyceps and bird's nest, which may influence pricing strategies [3] - The pricing strategy will consider market factors, product characteristics, and the scarcity of raw materials [4] Group 3: Research and Development Focus - The company is advancing in both consumer-oriented and clinical research, focusing on new product development and pharmacological validation [4] - Research efforts include improving product standards, production processes, and quality enhancement [4] - The company is exploring the potential of synthetic alternatives for Ajiao, although current capabilities are limited [4] Group 4: Industry Standards and Legal Protection - The company is actively working to combat counterfeit products through legal means and by promoting industry standards [5] - There is a belief that establishing industry standards will help regulate the market and support the company's growth [5] Group 5: Future Directions - The company is considering the integration of biological drugs into its product line, with a 49% stake in a new venture to enhance product offerings and market presence [5] - The focus will be on leveraging international platforms for broader market access and product diversification [5]